Skip to main content
Keymed Biosciences Inc. logo

Keymed Biosciences Inc. — Investor Relations & Filings

Ticker · 2162 LEI · 549300600S6M6SOT7P36 HKEX Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2026-04-29 Proxy Solicitation & In…
Country KY Cayman Islands
Listing HKEX 2162

About Keymed Biosciences Inc.

http://www.keymedbio.com

Keymed Biosciences Inc. is a biopharmaceutical company specializing in the in-house discovery and development of innovative biological therapies. The company focuses on therapeutic areas with urgent unmet clinical needs, primarily autoimmune diseases, other chronic conditions, and oncology. Keymed operates an integrated, full-chain platform covering source innovation, clinical development, production, and commercialization. It maintains a diversified and globally competitive product pipeline, leveraging its advanced R&D engine and cGMP-compliant manufacturing capabilities to deliver high-quality, affordable treatments.

Recent filings

Filing Released Lang Actions
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a "Form of Proxy" for use at the Annual General Meeting, which is a materials sent to shareholders to solicit their votes and provide information in advance of the meeting. This falls squarely under "Proxy Solicitation & Information Statement" (PSI).
2026-04-29 English
(1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; AND (4) NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2026-04-29 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of the Annual General Meeting, issued to shareholders with the agenda, resolutions to be voted on, proxy instructions, and related meeting details. It is not the actual meeting minutes or presentations (AGM-R), nor a results announcement (DVA). It is precisely the type of material distributed to shareholders to provide information and request votes ahead of the meeting, matching the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-29 English
2025 ANNUAL REPORT
Regulatory Filings
2026-04-29 English
SUPPLEMENTAL ANNOUNCEMENT TO DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES
M&A Activity Classification · 1% confidence The document is a supplement to a previously disclosed transaction involving the disposal of the company’s minority equity interest in another entity. It details conditions precedent, pricing, expected proceeds, and intended use of funds – all hallmarks of an M&A transaction announcement rather than an annual or interim report, earnings release, management discussion, or regulatory notice. Therefore, it fits the M&A Activity category.
2026-04-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a statutory monthly return filed to the Hong Kong Stock Exchange under Chapter 19B of the Listing Rules, detailing movements in authorised/issued share capital and public float sufficiency. It is neither an earnings release, annual or interim report, nor a discrete share issue announcement, but rather a routine regulatory compliance filing. This aligns with the fallback Regulatory Filings category.
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.